Last Updated: November 16, 2026

Investigational Drug Information for chiauranib

« Back to Dashboard


What is the drug development status for chiauranib?

chiauranib is an investigational drug.

There have been 17 clinical trials for chiauranib. The most recent clinical trial was a Phase 2 trial, which was initiated on August 13th 2024.

The most common disease conditions in clinical trials are Small Cell Lung Carcinoma, Lung Neoplasms, and Ovarian Neoplasms. The leading clinical trial sponsors are Chipscreen Biosciences, Ltd., Akeso, and Shenzhen Chipscreen Biosciences Co.Ltd.

There are seventy-five US patents protecting this investigational drug and twenty-seven international patents.

Recent Clinical Trials for chiauranib
TitleSponsorPhase
Chiauranib in Patients With Locally Advanced or Metastatic Pancreatic Ductal AdenocarcinomaChipscreen Biosciences, Ltd.PHASE2
Anti-PD-1 and CTLA-4 Bispecific Antibody AK104 in Combination With Chiauranib in Patients With Extensive Stage Small Cell Lung CancerChipscreen Biosciences, Ltd.Phase 1/Phase 2
Anti-PD-1 and CTLA-4 Bispecific Antibody AK104 in Combination With Chiauranib in Patients With Extensive Stage Small Cell Lung CancerAkesoPhase 1/Phase 2

See all chiauranib clinical trials

Clinical Trial Summary for chiauranib

Top disease conditions for chiauranib
Top clinical trial sponsors for chiauranib

See all chiauranib clinical trials

US Patents for chiauranib

Drugname Patent Number Patent Title Patent Assignee Estimated Expiration
chiauranib ⤷  Start Trial Non-solvated crystal, preparation method and application thereof Shenzhen Chipscreen Biosciences Co Ltd ⤷  Start Trial
chiauranib ⤷  Start Trial Functionalized long-chain hydrocarbon mono- and di-carboxylic acids and their use for the prevention or treatment of disease Espervita Therapeutics Inc ⤷  Start Trial
chiauranib ⤷  Start Trial Tead inhibitors and uses thereof ImageneBio Inc ⤷  Start Trial
chiauranib ⤷  Start Trial CXCR4 inhibitors and uses thereof X4 Pharmaceuticals Inc ⤷  Start Trial
>Drugname >Patent Number >Patent Title >Patent Assignee >Estimated Expiration

International Patents for chiauranib

Drugname Country Document Number Estimated Expiration Related US Patent
chiauranib Australia AU2019328530 2038-08-31 ⤷  Start Trial
chiauranib Brazil BR112021003467 2038-08-31 ⤷  Start Trial
chiauranib Canada CA3110735 2038-08-31 ⤷  Start Trial
chiauranib China CN112839649 2038-08-31 ⤷  Start Trial
>Drugname >Country >Document Number >Estimated Expiration >Related US Patent

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.